- Home
- NKSH vs DTIL Comparison
NKSH vs DTIL Comparison
Compare NKSH & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | DTIL |
|---|---|---|
| Founded | 1891 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 214.7M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NKSH | DTIL |
|---|---|---|
| Price | $40.58 | $7.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 23.9K | ★ 456.1K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | $8,176,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.92 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $27.00 | $3.53 |
| 52 Week High | $41.32 | $9.62 |
Technical Indicators
Market Signals| Indicator | NKSH | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 71.42 | 40.29 |
| Support Level | $34.46 | $6.30 |
| Resistance Level | N/A | $7.96 |
| Average True Range (ATR) | 1.39 | 0.50 |
| MACD | 0.43 | -0.16 |
| Stochastic Oscillator | 89.46 | 13.72 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).